Dexcom Q3 revenue slightly beats; $1 bln share buyback announced
Overview
Glucose biosensing firm's Q3 revenue grew 11% yr/yr, slightly beating analyst expectations
Adjusted EPS for Q3 beat analyst expectations
Company announced $1.0 bln share repurchase authorization
Outlook
Dexcom raises 2026 revenue guidance to $5.20-$5.25 bln, up 12-13% year-over-year
Company expects 2026 non-GAAP gross profit margin of about 64%
Dexcom sees 2026 non-GAAP operating margin of about 24% and adjusted EBITDA margin of about 32%
Result Drivers
US GROWTH - Co said Q3 revenue growth was led by 14% yr/yr increase in US sales
PRODUCT UPDATES - Co cited launch of redesigned Stelo experience with new features as a driver
PRODUCT ROLLOUT - Co advanced rollout of Dexcom G7 15 Day System in US and gained initial international clearances
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $1.34 bln | $1.33 bln (24 Analysts) |
Q3 Adjusted EPS | Beat | $0.73 | $0.67 (23 Analysts) |
Q3 Adjusted Net Income | Beat | $275.1 mln | $256.55 mln (20 Analysts) |
Q3 Adjusted Operating Income | Beat | $339.5 mln | $314.20 mln (23 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Dexcom Inc is $95.00, about 20.8% above its October 28 closing price of $78.62
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 24 three months ago
Reuters Recommended Reads
Oct 28 - Bausch + Lomb beats Q3 adjusted EPS estimates; raises FY outlook
Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption
Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)